‘The Most Significant Change in 20 Years’: Cancer Centers Prepare for Daraxonrasib Demand

Why It Matters

Daraxonrasib offers the first meaningful survival gain in decades for metastatic pancreatic cancer, reshaping treatment pathways and creating operational challenges for oncology networks nationwide.

Key Takeaways

• Patient inquiries for daraxonrasib have spiked across major U.S. cancer centers
• Hospitals are establishing expanded‑access protocols, EMR builds, and dedicated staffing
• Trial data showed 35% response and 13.1‑month median overall survival
• Supply chain and manufacturer approvals remain the biggest access hurdles

Pulse Analysis

The FDA’s expanded‑access designation for daraxonrasib marks a watershed moment for pancreatic cancer, a disease that accounts for just 3.2% of new cancers but 8.4% of cancer deaths in the United States. By permitting clinicians to prescribe the KRAS‑G12C inhibitor outside of formal trials, the agency has unlocked a pathway for patients who have exhausted standard chemotherapy. The trial’s 35% response rate and median overall survival of 13.1 months represent a dramatic improvement over historical outcomes, prompting a wave of inquiries from patients and referring physicians alike.

Health systems are scrambling to translate this clinical promise into operational reality. Major academic centers such as Mayo Clinic, UCSF, and Stanford are coordinating multidisciplinary teams—oncology, pharmacy, research, and regulatory affairs—to streamline the expanded‑access process. Initiatives include building electronic medical‑record order sets, training staff on dosing and toxicity monitoring, and securing research coordinators to manage data collection. Simultaneously, institutions are negotiating with Revolution Medicines to secure drug allocations, a step complicated by the unprecedented volume of requests and limited initial supply.

Looking ahead, the anticipated commercial launch of daraxonrasib could reshape the pancreatic oncology market, but the transition from compassionate use to full approval will test supply chains and reimbursement frameworks. Payers will need to assess cost‑effectiveness against the drug’s survival benefit, while providers must integrate biomarker testing—particularly KRAS‑G12C status—into standard diagnostic workflows. Centers that have already invested in infrastructure and collaborative trial networks will likely capture the early market share, positioning themselves as leaders in the next era of precision oncology for one of the deadliest cancers.